The stock of Editas Medicine Inc (NASDAQ:EDIT) is a huge mover today! About 193,629 shares traded hands. Editas Medicine Inc (NASDAQ:EDIT) has declined 54.82% since March 9, 2016 and is downtrending. It has underperformed by 62.24% the S&P500.
The move comes after 7 months negative chart setup for the $471.17M company. It was reported on Oct, 12 by Barchart.com. We have $11.43 PT which if reached, will make NASDAQ:EDIT worth $65.96 million less.
Analysts await Editas Medicine Inc (NASDAQ:EDIT) to report earnings on November, 8. After $-0.54 actual EPS reported by Editas Medicine Inc for the previous quarter, Wall Street now forecasts 20.37% negative EPS growth.
According to Zacks Investment Research, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.”
More notable recent Editas Medicine Inc (NASDAQ:EDIT) news were published by: Quotes.Wsj.com which released: “News Editas Medicine Inc.EDIT” on January 16, 2015, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on January 06, 2016, Bostonglobe.com published: “Editas Medicine raises $94.4 million in year’s first IPO” on February 02, 2016. More interesting news about Editas Medicine Inc (NASDAQ:EDIT) were released by: Ibtimes.com and their article: “Google-Backed Startup Editas Medicine Becomes First Gene Editing Company To …” published on January 05, 2016 as well as Globenewswire.com‘s news article titled: “Editas Medicine Expands Senior Management Team” with publication date: October 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.